Enfortumab Vedotin-Pembrolizumab in Advanced Urothelial Cancer | NEJM

Among patients with advanced urothelial cancer, 5-year survival with first-line platinum-based chemotherapy is relatively low. Enfortumab vedotin plus pembrolizumab may improve outcomes.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: nej.md/49ViJEe
#oncology #urology #clinicaltrials #nejm